Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT05267080
Active, not recruiting Observational

Registry on Percutaneous Electrochemotherapy

NCT05267080 · tracked via the Priya Life Science France tracker
Sponsor
Cardiovascular and Interventional Radiological Society of Europe
Phase
Observational
Started
2023-01-25
Last updated
2026-02-06

Condition(s) studied

Primary Liver CancerSecondary Liver Cancer

Investigational drug(s) / intervention(s)

CLINIPORATOR

CLINIPORATOR: The CLINIPORATOR is used to perform percutaneous electrochemotherapy on liver tumours.

Study summary

The Registry on Percutaneous ElectroChemoTherapy (RESPECT) is a post-market, prospective, non-randomized, observational study aiming at evaluating the effectiveness of percutaneous electrochemotherapy (ECT) for the treatment of liver cancer.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * 18 years or older * Primary or secondary liver cancer * Referral to local ablative treatment by multidisciplinary tumour board and decision to treat with pECT by interventional radiologist in charge * Planned treatment with pECT using the CLINIPORATOR * Signed informed consent form Exclusion Criteria: Pregnancy

Primary outcome measure(s)

  • Local Tumour Control — 12 months
    Based on the tumour status according to mRECIST assessment

Trial sites (15)

FacilityCityRegionStatus
Centre Hospitalier Universitaire de Montpellier Montpellier France
Hôpital Européen Georges-Pompidou Paris France
Institut Gustave Roussy Paris France
WEGE Klinik Bonn Germany
Städtisches Klinikum Braunschweig Braunschweig Germany
Universitätsklinikum Halle Halle Germany
Helios Park-Klinikum Leipzig Germany
University Hospital Regensburg Regensburg Germany
University of Szeged Szeged Hungary
Istituto Europeo di Oncologia Milan Italy
Fondazione Policlinico Universitario Campus Bio-Medico Rome Italy
Policlinico Universitario A. Gemelli Rome Italy
Vilnius University Hospital Santariškių Klinikos Vilnius Lithuania
Hospital Universitario y Politécnico La Fe Valencia Spain
Leeds Teaching Hospitals NHS Trust Leeds United Kingdom

More Cardiovascular and Interventional Radiological Society of Europe trials in France

BOne Metastases REgistry for Patients Undergoing cryoAbLation With curatIve purpoSe Recruiting
Chronic Limb-Threatening Ischemia Treated With Intravascular Lithotripsy Observational Study Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05267080 on ClinicalTrials.gov ↗ ← All trials in France